Public Employees Retirement Association of Colorado Has $104.06 Million Stock Position in Amgen Inc. (NASDAQ:AMGN)

Public Employees Retirement Association of Colorado lessened its position in Amgen Inc. (NASDAQ:AMGN) by 19.4% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 426,927 shares of the medical research company’s stock after selling 102,478 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Amgen were worth $104,063,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Birch Capital Management LLC raised its stake in shares of Amgen by 3.4% in the second quarter. Birch Capital Management LLC now owns 21,721 shares of the medical research company’s stock worth $5,295,000 after purchasing an additional 708 shares during the last quarter. Penserra Capital Management LLC lifted its position in shares of Amgen by 69.0% during the first quarter. Penserra Capital Management LLC now owns 42,244 shares of the medical research company’s stock valued at $10,510,000 after purchasing an additional 17,253 shares in the last quarter. Optiver Holding B.V. purchased a new position in Amgen during the first quarter worth about $5,578,000. Payden & Rygel grew its position in Amgen by 1.5% in the 1st quarter. Payden & Rygel now owns 134,340 shares of the medical research company’s stock worth $33,425,000 after purchasing an additional 2,050 shares in the last quarter. Finally, Arlington Financial Advisors LLC increased its stake in Amgen by 8.3% in the 2nd quarter. Arlington Financial Advisors LLC now owns 25,724 shares of the medical research company’s stock valued at $6,270,000 after buying an additional 1,962 shares during the last quarter. Hedge funds and other institutional investors own 74.73% of the company’s stock.

NASDAQ AMGN traded up $3.50 on Thursday, hitting $207.11. The stock had a trading volume of 104,955 shares, compared to its average volume of 2,603,943. The firm has a 50-day moving average of $219.46 and a 200-day moving average of $236.52. The company has a debt-to-equity ratio of 3.45, a quick ratio of 1.03 and a current ratio of 1.31. Amgen Inc. has a 52-week low of $200.47 and a 52-week high of $276.69. The company has a market capitalization of $117.61 billion, a price-to-earnings ratio of 20.94, a price-to-earnings-growth ratio of 1.55 and a beta of 0.68.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Monday, August 2nd. The medical research company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.29. The firm had revenue of $6.53 billion for the quarter, compared to analysts’ expectations of $6.43 billion. Amgen had a net margin of 22.55% and a return on equity of 99.85%. As a group, research analysts anticipate that Amgen Inc. will post 16.41 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 8th. Shareholders of record on Tuesday, August 17th were issued a $1.76 dividend. The ex-dividend date was Monday, August 16th. This represents a $7.04 annualized dividend and a dividend yield of 3.40%. Amgen’s payout ratio is currently 42.41%.

Several research firms have recently issued reports on AMGN. SVB Leerink initiated coverage on Amgen in a report on Sunday, September 19th. They issued a “hold” rating for the company. Robert W. Baird reiterated a “sell” rating on shares of Amgen in a research note on Thursday, August 5th. Morgan Stanley reduced their price target on shares of Amgen from $251.00 to $235.00 and set an “equal weight” rating for the company in a research report on Tuesday. Daiwa Capital Markets downgraded shares of Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 price objective for the company. in a report on Thursday, September 23rd. Finally, William Blair reissued a “hold” rating on shares of Amgen in a report on Friday, September 17th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $244.58.

Amgen Company Profile

Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.

Featured Article: What is a conference call?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.